Literature DB >> 22382140

[Molecular mechanisms of atrial fibrillation: potential role of microRNAs as new therapeutic targets and potential biomarkers].

R Wakili1, S Clauß, S Kääb.   

Abstract

Atrial fibrillation represents the most common form of clinical arrhythmia in daily routine. However, current therapeutic options are still limited and a better understanding of the underlying molecular mechanisms is expected to contribute to the development of new therapeutic strategies. The scientific field of microRNA research has received a lot of attention in recent years, especially regarding cardiovascular research. This article gives a brief overview of the most recent developments in microRNA research in the field of atrial fibrillation and atrial remodelling processes. Furthermore, the clinical perspective of microRNAs as new therapeutic targets and as potential biomarkers is discussed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22382140     DOI: 10.1007/s00059-012-3594-0

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  25 in total

Review 1.  New ideas about atrial fibrillation 50 years on.

Authors:  Stanley Nattel
Journal:  Nature       Date:  2002-01-10       Impact factor: 49.962

Review 2.  MicroRNAs and atrial fibrillation: new fundamentals.

Authors:  Zhiguo Wang; Yanjie Lu; Baofeng Yang
Journal:  Cardiovasc Res       Date:  2010-11-04       Impact factor: 10.787

3.  Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation: an independent predictor of procedural failure.

Authors:  Atul Verma; Oussama M Wazni; Nassir F Marrouche; David O Martin; Fethi Kilicaslan; Stephen Minor; Robert A Schweikert; Walid Saliba; Jennifer Cummings; J David Burkhardt; Mandeep Bhargava; William A Belden; Ahmad Abdul-Karim; Andrea Natale
Journal:  J Am Coll Cardiol       Date:  2005-01-18       Impact factor: 24.094

Review 4.  Recent advances in the molecular pathophysiology of atrial fibrillation.

Authors:  Reza Wakili; Niels Voigt; Stefan Kääb; Dobromir Dobrev; Stanley Nattel
Journal:  J Clin Invest       Date:  2011-08-01       Impact factor: 14.808

Review 5.  Atrial fibrillation pathophysiology: implications for management.

Authors:  Yu-ki Iwasaki; Kunihiro Nishida; Takeshi Kato; Stanley Nattel
Journal:  Circulation       Date:  2011-11-15       Impact factor: 29.690

6.  miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling.

Authors:  Rudy F Duisters; Anke J Tijsen; Blanche Schroen; Joost J Leenders; Viola Lentink; Ingeborg van der Made; Veronica Herias; Rick E van Leeuwen; Mark W Schellings; Paul Barenbrug; Jos G Maessen; Stephane Heymans; Yigal M Pinto; Esther E Creemers
Journal:  Circ Res       Date:  2008-12-18       Impact factor: 17.367

7.  Changes in connexin expression and the atrial fibrillation substrate in congestive heart failure.

Authors:  Brett Burstein; Philippe Comtois; Georghia Michael; Kunihiro Nishida; Louis Villeneuve; Yung-Hsin Yeh; Stanley Nattel
Journal:  Circ Res       Date:  2009-10-29       Impact factor: 17.367

8.  The German Competence Network on Atrial Fibrillation (AFNET).

Authors:  Günter Breithardt; Dobromir Dobrev; Nicolas Doll; Andreas Goette; Boris Hoffmann; Paulus Kirchhof; Ilka Köster; Karl-Heinz Kuck; Angelika Leute; Thomas Meinertz; Michael Näbauer; Michael Oeff; Ursula Ravens; Andreas Schuchert; Claudia Sprenger; Gerhard Steinbeck; Stephan Willems
Journal:  Herz       Date:  2008-12       Impact factor: 1.443

9.  miR-1 overexpression enhances Ca(2+) release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2.

Authors:  Dmitry Terentyev; Andriy E Belevych; Radmila Terentyeva; Mickey M Martin; Geraldine E Malana; Donald E Kuhn; Maha Abdellatif; David S Feldman; Terry S Elton; Sandor Györke
Journal:  Circ Res       Date:  2009-01-08       Impact factor: 17.367

10.  Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats.

Authors:  M C Wijffels; C J Kirchhof; R Dorland; M A Allessie
Journal:  Circulation       Date:  1995-10-01       Impact factor: 29.690

View more
  4 in total

1.  The Role of MicroRNAs in Antiarrhythmic Therapy for Atrial Fibrillation.

Authors:  Sebastian Clauss; Moritz F Sinner; Stefan Kääb; Reza Wakili
Journal:  Arrhythm Electrophysiol Rev       Date:  2015-12-01

2.  MicroRNAs as Biomarkers for Acute Atrial Remodeling in Marathon Runners (The miRathon Study--A Sub-Study of the Munich Marathon Study).

Authors:  Sebastian Clauss; Reza Wakili; Bianca Hildebrand; Stefan Kääb; Eva Hoster; Ina Klier; Eimo Martens; Alan Hanley; Henner Hanssen; Martin Halle; Thomas Nickel
Journal:  PLoS One       Date:  2016-02-09       Impact factor: 3.240

3.  Coding and non-coding variants in the SHOX2 gene in patients with early-onset atrial fibrillation.

Authors:  Sandra Hoffmann; Sebastian Clauss; Ina M Berger; Birgit Weiß; Antonino Montalbano; Ralph Röth; Madeline Bucher; Ina Klier; Reza Wakili; Hervé Seitz; Eric Schulze-Bahr; Hugo A Katus; Friederike Flachsbart; Almut Nebel; Sabina Pw Guenther; Erik Bagaev; Wolfgang Rottbauer; Stefan Kääb; Steffen Just; Gudrun A Rappold
Journal:  Basic Res Cardiol       Date:  2016-04-30       Impact factor: 17.165

4.  Analysis of the microRNA signature in left atrium from patients with valvular heart disease reveals their implications in atrial fibrillation.

Authors:  Rosa Doñate Puertas; Audrey Jalabert; Emmanuelle Meugnier; Vanessa Euthine; Philippe Chevalier; Sophie Rome
Journal:  PLoS One       Date:  2018-05-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.